Antibiotics, Antineoplastic

• 

  Subject Areas on Research

  • A micro-CT analysis of murine lung recruitment in bleomycin-induced lung injury. 
  • A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. 
  • A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation. 
  • A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. 
  • A quantitative study of the intracellular fate of pH-responsive doxorubicin-polypeptide nanoparticles. 
  • A synthetic mimic of the secretory granule for drug delivery. 
  • A tracer dose of technetium-99m-labeled liposomes can estimate the effect of hyperthermia on intratumoral doxil extravasation. 
  • Adriamycin-induced senescence in breast tumor cells involves functional p53 and telomere dysfunction. 
  • Adult Lung Spheroid Cells Contain Progenitor Cells and Mediate Regeneration in Rodents With Bleomycin-Induced Pulmonary Fibrosis. 
  • Amelioration of the cytotoxic effects of chemotherapeutic agents by grape seed proanthocyanidin extract. 
  • An approach to monoclonal gammopathies in the elderly. 
  • Anthracenedione activation by NADPH-cytochrome P-450 reductase; comparison with anthracyclines. 
  • Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group. 
  • Apoptosis induces expression of sphingosine kinase 1 to release sphingosine-1-phosphate as a "come-and-get-me" signal. 
  • Aqueous shunt devices compared with trabeculectomy with Mitomycin-C for children in the first two years of life. 
  • Aqueous shunt devices compared with trabeculectomy with mitomycin-C for children in the first two years of life. 
  • Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174? 
  • Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. 
  • Bis(alkylamino)anthracenedione antineoplastic agent metabolic activation by NADPH-cytochrome P-450 reductase and NADH dehydrogenase: diminished activity relative to anthracyclines. 
  • Burden of disease predicts response to isolated limb infusion with melphalan and actinomycin D in melanoma. 
  • CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine. 
  • Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification. 
  • Chemodosimetry of in vivo tumor liposomal drug concentration using MRI. 
  • Chemoreduction with topical mitomycin C prior to resection of extensive squamous cell carcinoma of the conjunctiva. 
  • Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting. 
  • Clinical trial of high dose hyperthermic intravesical mitomycin C for intermediate and high-risk non-muscle invasive bladder cancer during BCG shortage. 
  • Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin. 
  • Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program. 
  • Creatine supplementation reduces doxorubicin-induced cardiomyocellular injury. 
  • Cytotoxic, antifouling bromotyramines: a synthetic study on simple marine natural products and Their analogues. 
  • Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity. 
  • Development of novel targeted therapies in the treatment of malignant glioma. 
  • Diabetic urethropathy compounds the effects of diabetic cystopathy. 
  • Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells. 
  • Dose-finding study of oral idarubicin and cyclophosphamide in first-line treatment of elderly patients with metastatic breast cancer. 
  • Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. 
  • Doxorubicin-conjugated chimeric polypeptide nanoparticles that respond to mild hyperthermia. 
  • Doxorubicin-conjugated polypeptide nanoparticles inhibit metastasis in two murine models of carcinoma. 
  • Doxorubicin-induced cardiac dysfunction in unselected patients with a history of early-stage breast cancer. 
  • Drug development of lyso-thermosensitive liposomal doxorubicin: Combining hyperthermia and thermosensitive drug delivery. 
  • Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer. 
  • Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238. 
  • Epirubicin: is it like doxorubicin in breast cancer? A clinical review. 
  • Epithelial Regeneration After Doxorubicin Arises Primarily From Early Progeny of Active Intestinal Stem Cells. 
  • Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer. 
  • Erythropoietin protects cardiac myocytes against anthracycline-induced apoptosis. 
  • Evaluation of an elastin-like polypeptide-doxorubicin conjugate for cancer therapy. 
  • Exacerbation of anthracycline-induced early chronic cardiomyopathy with ATRA: role of B-type natriuretic peptide as an indicator of cardiac dysfunction. 
  • Follicular mucinosis as a presenting sign of acute myeloblastic leukemia. 
  • Genetically Encoding Albumin Binding into Chemotherapeutic-loaded Polypeptide Nanoparticles Enhances Their Antitumor Efficacy. 
  • Genome-Wide Association Study Identifies ROBO2 as a Novel Susceptibility Gene for Anthracycline-Related Cardiomyopathy in Childhood Cancer Survivors. 
  • Heated Intravesical Chemotherapy: Biology and Clinical Utility. 
  • Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin. 
  • Histology of conjunctival vascular endothelium after filtering surgery with mitomycin C in rabbits. 
  • Holding back the sea: the role for maintenance chemotherapy in metastatic breast cancer. 
  • Hyperthermia mediated liposomal drug delivery. 
  • Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors. 
  • Imprinted CDKN1C is a tumor suppressor in rhabdoid tumor and activated by restoration of SMARCB1 and histone deacetylase inhibitors. 
  • In vivo inhibition of PC-3 human androgen-independent prostate cancer by a targeted cytotoxic bombesin analogue, AN-215. 
  • In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: illustration of targeted delivery. 
  • Induction of tenascin in rat lungs undergoing bleomycin-induced pulmonary fibrosis. 
  • Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238. 
  • Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238. 
  • Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. 
  • Interaction of FANCD2 and NBS1 in the DNA damage response. 
  • Intrinsic Xenobiotic Resistance of the Intestinal Stem Cell Niche. 
  • Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. 
  • Laser suture lysis after mitomycin C trabeculectomy. 
  • Left ventricular assist device as destination therapy in doxorubicin-induced cardiomyopathy. 
  • Letter: Antitumor agents. XIII. Isolation and absolute configuration of carminomycin I from Streptosporangium sp. 
  • Limb preservation with isolated limb infusion for locally advanced nonmelanoma cutaneous and soft-tissue malignant neoplasms. 
  • Long-term pegylated liposomal doxorubicin use in recurrent ovarian carcinoma. 
  • Lymphangioleiomyomatosis. 
  • MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy. 
  • Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects. 
  • Management of Lung Transplant Bronchial Stenosis With Mitomycin C. 
  • Materials characterization of the low temperature sensitive liposome (LTSL): effects of the lipid composition (lysolipid and DSPE-PEG2000) on the thermal transition and release of doxorubicin 
  • Mechanisms of action of rapamycin in gliomas. 
  • Mitochondrial DNA-depleted A549 cells are resistant to bleomycin. 
  • Mitomycin C and menadione for the treatment of lung cancer: a phase II trial. 
  • Modeling the Effect of TNF-α upon Drug-Induced Toxicity in Human, Tissue-Engineered Myobundles. 
  • Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer: current evidence and underlying mechanisms. 
  • Monocytoid differentiation of freshly isolated human myeloid leukemia cells and HL-60 cells induced by the glutamine antagonist acivicin. 
  • Multicenter phase II study of a 28-day regimen of orally administered eniluracil and fluorouracil in the treatment of patients with anthracycline- and taxane-resistant advanced breast cancer. 
  • Mutagen sensitivity to benzo(a)pyrene diol epoxide and the risk of squamous cell carcinoma of the head and neck. 
  • Nanoparticle formulation improves doxorubicin efficacy by enhancing host antitumor immunity. 
  • Negative regulation of myofibroblast differentiation by PTEN (Phosphatase and Tensin Homolog Deleted on chromosome 10). 
  • Neihumicin, a new cytotoxic antibiotic from Micromonospora neihuensis. II. Structural determination and total synthesis. 
  • Non-invasive monitoring of intra-tumor drug concentration and therapeutic response using optical spectroscopy. 
  • Novel role of 4-hydroxy-2-nonenal in AIFm2-mediated mitochondrial stress signaling. 
  • Oligonucleotide enhanced cytotoxicity of Idarubicin for lymphoma cells. 
  • Oxidative DNA base damage in MCF-10A breast epithelial cells at clinically achievable concentrations of doxorubicin. 
  • Pentostatin (2'-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma. 
  • Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. 
  • Phase II evaluation of aclarubicin in advanced breast cancer: a Southeastern Cancer Study Group trial. 
  • Phase II evaluation of aclarubicin in lung cancer: a Southeastern Cancer Study Group Trial. 
  • Phase II evaluation of aclarubicin in refractory multiple myeloma: a Southeastern Cancer Study Group Trial. 
  • Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304). 
  • Phase II trial of diaziquone in anthracycline-resistant adult soft tissue and bone sarcoma patients: a Southeastern Cancer Study Group Trial. 
  • Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336). 
  • Post transfusion non-cardiogenic pulmonary edema in a patient with chemotherapy-related hemolytic uremic syndrome. 
  • Preclinical Evaluation of Promitil, a Radiation-Responsive Liposomal Formulation of Mitomycin C Prodrug, in Chemoradiotherapy. 
  • Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. 
  • Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas. 
  • Prospective analysis of DNA damage and repair markers of lung cancer risk from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. 
  • Protection against daunorubicin cytotoxicity by expression of a cloned human carbonyl reductase cDNA in K562 leukemia cells. 
  • RNA Aptamer-targeted Inhibition of NF-κB Suppresses Non-small Cell Lung Cancer Resistance to Doxorubicin. 
  • Radiation Therapy for Soft Tissue Sarcoma: Indications and Controversies for Neoadjuvant Therapy, Adjuvant Therapy, Intraoperative Radiation Therapy, and Brachytherapy. 
  • Radiofrequency Ablation Duration per Tumor Volume May Correlate with Overall Survival in Solitary Hepatocellular Carcinoma Patients Treated with Radiofrequency Ablation Plus Lyso-Thermosensitive Liposomal Doxorubicin. 
  • Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone. 
  • Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M. 
  • Rationale and design of the Children's Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure. 
  • Redox proteomic identification of HNE-bound mitochondrial proteins in cardiac tissues reveals a systemic effect on energy metabolism after doxorubicin treatment. 
  • Regression of U-87 MG human glioblastomas in nude mice after treatment with a cytotoxic somatostatin analog AN-238. 
  • Regulation of the ATM-activator protein Aven by CRM1-dependent nuclear export. 
  • Relationship of acivicin-induced monocytoid differentiation of human myeloid leukemia cells to acivicin-induced modulation of growth factor, cytokine, and protooncogene mRNA expression. 
  • Results of NC-6300 (Nanoparticle Epirubicin) in an Expansion Cohort of Patients with Angiosarcoma. 
  • Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. 
  • Rubidazone in the treatment of recurrent acute leukemia in children. A Pediatric Oncology Group Study. 
  • Safe administration of hyperbaric oxygen after bleomycin: a case series of 15 patients. 
  • Safety and efficacy of intravesical chemotherapy and hyperthermia in the bladder: results of a porcine study. 
  • Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice. 
  • Selective cardiac surveillance in patients with gynecologic cancer undergoing treatment with pegylated liposomal doxorubicin (PLD). 
  • Selective targeting of nanocarriers to neutrophils and monocytes. 
  • Self-assembling chimeric polypeptide–doxorubicin conjugate nanoparticles that abolish tumours after a single injection 
  • Simultaneous measurement of liposome extravasation and content release in tumors. 
  • Structural optimization of a "smart" doxorubicin-polypeptide conjugate for thermally targeted delivery to solid tumors. 
  • Successful treatment of two children with Langerhans' cell histiocytosis with 2'-deoxycoformycin. 
  • Supportive care of the marrow transplant recipient: the Seattle Experience. 
  • Suppository administration of chemotherapeutic drugs with concomitant radiation for rectal cancer. 
  • Suppressor of fused negatively regulates beta-catenin signaling. 
  • Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. 
  • Systemic anti-tumour effects of local thermally sensitive liposome therapy. 
  • Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status. 
  • Targeted drug delivery to C6 glioma by transferrin-coupled liposomes. 
  • Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancers. 
  • Targeting tumor microvessels using doxorubicin encapsulated in a novel thermosensitive liposome. 
  • The CO/HO system reverses inhibition of mitochondrial biogenesis and prevents murine doxorubicin cardiomyopathy. 
  • The TOR kinases link nutrient sensing to cell growth. 
  • The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas. 
  • The genetic underpinnings of anthracycline-induced cardiomyopathy predisposition. 
  • The non-covalent interaction of pyrrolo[2, 1-c] [1, 4]benzodiazepine-5, 11-diones with DNA. 
  • The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. 
  • The role of cavitation in acoustically activated drug delivery. 
  • Therapy for granulomatous angiitis. 
  • Thermosensitive liposomes: extravasation and release of contents in tumor microvascular networks. 
  • Treatment outcomes in the tube versus trabeculectomy study after one year of follow-up. 
  • Tumor cell-derived exosomes home to their cells of origin and can be used as Trojan horses to deliver cancer drugs. 
  • Tumor cells upregulate normoxic HIF-1α in response to doxorubicin. 
  • Tumor microvascular permeability is a key determinant for antivascular effects of doxorubicin encapsulated in a temperature sensitive liposome. 
  • Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer. 
  • Ultrasound guided pO2 measurement of breast cancer reoxygenation after neoadjuvant chemotherapy and hyperthermia treatment. 
  • United States Cutaneous Lymphoma Consortium recommendations for treatment of cutaneous lymphomas during the COVID-19 pandemic. 
  • Unresectable hepatocellular carcinoma treated with radiotherapy and/or chemoembolization. 
  • Using optical spectroscopy to longitudinally monitor physiological changes within solid tumors. 
  • nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors. 
  • β-arrestin deficiency protects against pulmonary fibrosis in mice and prevents fibroblast invasion of extracellular matrix. 
• 

  Keywords of People

  • Linardic, Corinne Mary, Associate Professor of Pediatrics, Cell Biology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Palmer, Gregory M., Associate Professor of Radiation Oncology, Radiation Oncology
  • Pang, Herbert, Adjunct Assistant Professor in the Department of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Biomedical Engineering